XFOR compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

XFORX4 Pharmaceuticals, Inc

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

XFORX4 Pharmaceuticals, Inc

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only XFOR 4

—Genzyme Corporation ("Genzyme")unlistedsupplier

—Abbisko Therapeutics Co. Ltd. ("Abbisko")unlistedcustomer

—Norgine Pharma UK Ltd. ("Norgine")unlistedcustomer

—Taiba Middle East Fz LLC ("taiba rare")unlistedcustomer

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

XFORX4 Pharmaceuticals, Inc

3.04· pre 3.04· delayed

Mkt cap$313.5MRevenue$3MQ3 FY26Revenue$35MFY25

AMGNAmgen Inc

461.49· pre 453.00· delayed

Pre-marketNov 6 '26delayed

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

Pre-marketNov 6 '26delayed

XFORX4 Pharmaceuticals, Inc

AMGNAmgen Inc

3.04pre 3.04delayed

Price

461.49pre 453.00delayed

$313.5M

Mkt cap

$249.0B

Q3 FY26$3M

Revenue

$10.4BQ3 FY26

FY25$35M

Revenue

$36.8BFY25

XFOR3.04vsAMGN461.49Pre-marketNov 6 '26delayed